Dopamine D2 Receptor Splice Variants and Autoreceptor Function
多巴胺 D2 受体剪接变体和自身受体功能
基本信息
- 批准号:9241697
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-10-01 至 2020-09-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAgonistAlternative SplicingAutoreceptorsBasic ScienceBehaviorBiological ModelsCalciumCalcium-Binding ProteinsCell LineCocaineCorpus striatum structureDevelopmentDiagnosisDopamineDopamine D2 ReceptorDopamine ReceptorDrug AddictionDrug ControlsDrug abuseDrug usageElectrophysiology (science)ExhibitsFamilyFunctional disorderG-Protein-Coupled ReceptorsG-substrateGTP-Binding Protein alpha Subunits, GsGTP-Binding ProteinsKnock-outKnockout MiceLeftMammalian CellMeasuresMediatingMembraneMental disordersMidbrain structureMilitary PersonnelModelingMotor ActivityMusNeuronsOrganismParkinson DiseasePathway interactionsPatientsPharmacological TreatmentPhenotypePopulationPropertyProteinsRNA SplicingRecombinantsRegulationResourcesRewardsRodentSchizophreniaSignal TransductionTaste aversionTestingUnited StatesUpdateVariantVeteransVirusWild Type MouseWorkbasebehavior measurementbehavioral sensitizationdesensitizationdopamine systemdopaminergic neurondrug seeking behaviorinduced pluripotent stem cellinsightmembermutantnervous system disorderneurochemistryneuropsychiatric disorderpostsynapticpreferencepresynapticreceptorreuptakestimulant abusesubstance abuse treatmenttherapeutic target
项目摘要
The five subtypes of dopamine receptors (D1-D5) are members of the superfamily of G protein-coupled
receptors. The D1 and D2 subtypes are the most abundant and mediate most classic dopamine-dependent
behaviors. This application is focused on the D2 receptor and, in particular, on the functional significance of
a 29-residue fragment in the third cytoplasmic loop that is alternatively spliced to produce the short and long
forms of the D2 receptor, D2S and D2L. Considerable evidence indicates that the D2 receptor is the primary
autoreceptor that regulates DA neuron activity and DA release, and it is widely accepted that D2S is that
autoreceptor, whereas D2L is the postsynaptic receptor expressed in striatal medium spiny neurons. In
contrast, our work supports a model in which rodent dopamine neurons express both splice variants, and
both function as autoreceptors with some subtle differences. We have determined that one difference
between the splice variants is their rate of calcium-dependent desensitization and we now propose to
evaluate the significance of this difference for cocaine-induced sensitization, reward, and aversion, while
also comparing other functional properties of the splice variants. In the first specific aim we will compare
additional aspects of the function of D2L and D2S as the presynaptic autoreceptor that inhibits dopamine
release, dopamine neuron firing, and locomotor activity. We will use virus-mediated expression of D2L or
D2S in the midbrain of D2 receptor null-mutant (D2-KO) mice and of mice with regional D2 receptor knock-
out, to restore the expression of either D2L or D2S in dopamine neurons prior to assessing measures of D2
autoreceptor activity. We will also determine if both variants regulate G protein-mediated signaling in striatal
neurons. This aim will focus on receptor localization and regulation of dopamine release and reuptake, and
will explore the hypotheses that cocaine alters the distribution or expression of the variants. The second
specific aim is based on alternative hypotheses that a cocaine-induced somatodendritic autoreceptor
switch from D2S to D2L triggers or reflects other changes that produce behavioral sensitization, conditioned
place preference to cocaine, and decreased aversion, or that the phenotype switch is a compensatory
mechanism that mediates decreased reward and increased aversion. In this aim we will test these
hypotheses by measuring cocaine-induced behavioral sensitization, conditioned place preference, and
conditioned taste aversion in mice expressing only D2S or D2L autoreceptors. Experimental support for
either hypothesis will provide valuable insight into the relevance of D2 receptor alternative splicing for DA
neuron function.
多巴胺受体的五种亚型(D1-D5)是G蛋白偶联受体超家族的成员。
受体。D1和D2亚型是最丰富的,介导最典型的多巴胺依赖性
行为。本申请集中于D2受体,特别是D2受体的功能意义。
第三个细胞质环中的29个残基片段,其选择性剪接以产生短和长的
D2受体,D2 S和D2 L。大量证据表明,D2受体是主要的
D2 S是调节DA神经元活性和DA释放的自身受体,并且广泛接受D2 S是
D2 L是自身受体,而D2 L是在纹状体中等多刺神经元中表达的突触后受体。在
相反,我们的工作支持一个模型,其中啮齿动物多巴胺神经元表达两种剪接变体,
两者都作为自身感受器起作用,但有一些细微的差异。我们已经确定了一个区别
剪接变体之间的差异是它们的钙依赖性脱敏率,我们现在提出,
评估可卡因诱导的敏感性,奖励和厌恶的这种差异的意义,
还比较剪接变体的其它功能性质。在第一个具体目标中,我们将比较
D2 L和D2 S作为抑制多巴胺的突触前自身受体的功能的其他方面
释放、多巴胺神经元放电和自发活动。我们将使用病毒介导的D2 L或
D2受体缺失突变(D2-KO)小鼠和局部D2受体敲除小鼠中脑中的D2 S。
为了在评估D2的测量之前恢复多巴胺神经元中D2 L或D2 S的表达,
自体受体活性我们还将确定这两种变体是否调节纹状体中G蛋白介导的信号传导。
神经元这一目标将集中在受体定位和调节多巴胺的释放和再摄取,
将探讨可卡因改变变异体的分布或表达的假设。第二
具体目标是基于另一种假设,即可卡因诱导的体树突自身受体
从D2 S到D2 L的转换触发或反映了其他变化,这些变化产生了行为敏感化、条件化
位置偏好可卡因,厌恶减少,或者表型转换是一种补偿性的,
一种调节奖励减少和厌恶增加的机制。为此,我们将测试这些
假设通过测量可卡因诱导的行为敏感化,条件性位置偏好,
仅表达D2 S或D2 L自身受体的小鼠的条件性味觉厌恶。实验支持
这两种假设都将为D2受体选择性剪接与DA的相关性提供有价值的见解。
神经元功能
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KIM Arthur NEVE其他文献
KIM Arthur NEVE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KIM Arthur NEVE', 18)}}的其他基金
Dopamine D2 Receptor Mutations and Hyperkinetic Movement Disorders
多巴胺 D2 受体突变和多动性运动障碍
- 批准号:
10640977 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Characterization of a DRD2 Variant that is Associated With a Movement Disorder
与运动障碍相关的 DRD2 变体的特征
- 批准号:
10029640 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Molecular and Behavioral Analysis of Dopamine Receptor Function
多巴胺受体功能的分子和行为分析
- 批准号:
8397575 - 财政年份:2010
- 资助金额:
-- - 项目类别:
Molecular and Behavioral Analysis of Dopamine Receptor Function
多巴胺受体功能的分子和行为分析
- 批准号:
8259083 - 财政年份:2010
- 资助金额:
-- - 项目类别:
Molecular and Behavioral Analysis of Dopamine Receptor Function
多巴胺受体功能的分子和行为分析
- 批准号:
8195874 - 财政年份:2010
- 资助金额:
-- - 项目类别:
Molecular and Behavioral Analysis of Dopamine Receptor Function
多巴胺受体功能的分子和行为分析
- 批准号:
7931040 - 财政年份:2010
- 资助金额:
-- - 项目类别:
CHARACTERIZATION OF NOVEL G-ALPHA INTERACTING PROTEINS
新型 G-α 相互作用蛋白的表征
- 批准号:
6027297 - 财政年份:1999
- 资助金额:
-- - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
-- - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
-- - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
-- - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
-- - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)